Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

NCT04622865 Phase 2 UNKNOWN

Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.

Details

Lead sponsor	AB Science
Phase	Phase 2
Status	UNKNOWN
Enrolment	200
Start date	2020-06-01
Completion	2023-12

Conditions

• SARS-CoV 2
• COVID-19
• Coronavirus Disease 2019

Interventions

• Masitinib
• Isoquercetin
• Best Supportive Care

Primary outcomes

• Clinical status of patients at day-15 using a 7-point ordinal scale — 15 days
  Ordinal scale defined as follows: 1. Not hospitalized, no limitations on activities; 2.Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.

Countries

France